Agilon Health Raised to Neutral From Sell by Citigroup
Citi Upgrades Agilon Health(AGL.US) to Hold Rating, Raises Target Price to $2.25
Agilon Health Initiated With a Hold at Needham
Agilon Health Analyst Ratings
RBC Capital Maintains Agilon Health(AGL.US) With Buy Rating, Maintains Target Price $3
RBC Capital Reaffirms Their Buy Rating on Agilon Health (AGL)
Goldman Sachs Maintains Agilon Health(AGL.US) With Hold Rating, Announces Target Price $2.5
Macquarie Initiates Agilon Health(AGL.US) With Hold Rating, Announces Target Price $3
Agilon Health Price Target Announced at $3.00/Share by Macquarie
Agilon Health Initiated at Neutral by Macquarie
Agilon Health Initiated at Market Perform by Bernstein
Bernstein Initiates Agilon Health(AGL.US) With Hold Rating, Announces Target Price $2.5
Agilon Health Analyst Ratings
RBC Capital Maintains Agilon Health(AGL.US) With Buy Rating, Maintains Target Price $3
RBC Capital Reaffirms Their Buy Rating on Agilon Health (AGL)
Wells Fargo Maintains Agilon Health(AGL.US) With Buy Rating, Cuts Target Price to $4
Truist Financial Maintains Agilon Health(AGL.US) With Hold Rating
Citi Maintains Agilon Health(AGL.US) With Sell Rating, Cuts Target Price to $1.75
Agilon Health Is Maintained at Underweight by Barclays
Agilon Health Analyst Ratings
No Data